Per the new National Institute for Health and Care Excellence (NICE) guidance, the once-a-day pill will be available on the NHS for adults who have tested positive for the epidermal growth factor receptor (EGFR) mutation.
This is a change from the committee’s initial decision which found the tyrosine kinase inhibitor to not be a cost-effective use of NHS resources.
In clinical trials the treatment achieved overall survival rates of 34.1 months compared with 26.8 months, compared to patients who took AstraZeneca’s Irissa (gefitinib), which is already recommended by NICE.
It was also found to increase the length of time before the disease worsened – 14.7 months compared with 9.2 months for Irissa.
It was however noted that Vizimpro had a higher incidence of side effects than the AZ drug, so a lower dose may be needed…